Skip to main content

Nutrition/Obesity

Dr. John Cush
@RheumNow
Two Prescriptions, One Patient Obesity, in particular in PsA was widely covered at #ACR26. In the Swiss SCQM registry, 63.6% of 2,087 patients with PsA were overweight or obese, compared with 31% overweight and 12% obese in the Swiss population, and higher BMI tracked disease https://t.co/Ys5wTvQ2r9
Dr. John Cush
@RheumNow
Biologic Dosing and Obesity A 46-year-old with pSa and a BMI of 38 still has active disease on adalimumab (Humira) 40 mg every other week. What do you do? Stephen Balevic, MD, PhD, discusses this question in "Prescribing the Right Dose: How Obesity Alters Drug https://t.co/0SGQGs32U2
Antoni Chan MD (Prof)
@synovialjoints
ACR26 summary, obesity in PsA: 81.8% prevalence of overweight or obesity in a US cohort, lower ACR50 at higher BMI on bimekizumab, and higher ACR50 with ixekizumab plus tirzepatide at 52 weeks. @rheumnow #ACR26 Abstract#2015 Abstract#1305 Abstract#2942
Audrey Gibson
@Gibson_RheumPAC

TOGETHER-PsA by Merola et al may be a practice-changing obesity story. Adding tirzepatide to ixekizumab improved joint outcomes at 52 weeks. Treating inflammation alone may not be enough for some patients with PsA. @rheumnow #ACR2026 #ACRBest Abstract#2942

Audrey Gibson
@Gibson_RheumPAC
Merola et al. (TOGETHER-PsA): In PsA + obesity, adding tirzepatide to ixekizumab improved ACR50 and several disease-activity measures at week 52. Randomized data; open-label design. @rheumnow #ACR2026 Abstract#2942
Audrey Gibson
@Gibson_RheumPAC

Merola et al, TOGETHER-PsA: At 52 weeks, ACR50 was 43.7% with ixekizumab + tirzepatide vs 15.7% with ixekizumab alone. A 28-point difference! Is addressing obesity becoming essential to optimal PsA care? @rheumnow #ACR2026 #ACRBest Abstract#2942

Falls Hide in Plain Sight in Rheumatic Disease

Jiha Lee, MD

Katherine Wysham, MD, in the session “Rheumatology for Every Age” at ACR 2026 noted that falls are common in people with arthritis and underreported. A fall tends to start a cycle: lost confidence, less going out, reduced social participation, deconditioning, and then more falls and fractures.

Dr. John Cush
@RheumNow
Weight Loss and Arthritis: A focus on patient-reported outcomes Obesity is associated with poorer physical function and treatment response in rheumatoid arthritis (RA). The ACR guideline on exercise, rehabilitation and diet supports discussing healthy body weight as part of https://t.co/GynYYRqC4T
Adela Castro
@AdelaCastro222
ACR 2026 guidelines for management of OA 1. Self management programs: educate pts on the disease and involve them in their care. 2. PT/OT-Key! 3. Mobility aids if limited walking. 4. Exercise! all of them recommended. 5. Wt loss if hip/knee OA and overwt or obese 6. Topical https://t.co/JnbNaZ3CSw
Dr. John Cush
@RheumNow
ACR 2026 – Day 1 Report ACR Convergence was off to a big start with the year in review, posters and plenary sessions. Here are a few of our favorite presentations from today's Plenary I session at ACR Convergence. 2/5 plenary abstracts focused on weight loss, one on artificial https://t.co/d1u0nElhov
×